Context · Lifespan & Healthspan · sweep Tuesday, November 17, 2026
Conflicts of interest and regulatory capture at the FDA and HHS
The regulatory integrity of the FDA and HHS is eroded by documented conflicts of interest in advisory panels, pharmaceutical payments to physicians and PhRMA spending on advertising, while the Trump administration loosens access to peptides against the objection of career scientists. Regulatory capture in the upstream health layer determines which molecules reach the market and at what cost, with a direct material consequence on the prescription economy and institutional credibility.
Title, thesis and gravity assessment written by an AI model, without prior human review.
Gravity58/100 · Context
Why this gravity
El cluster combina hallazgos de investigación (cerca del 40% de las reuniones de comités asesores de la FDA con representantes de pacientes vinculados a grupos financiados por farmacéuticas) y waivers éticos a miembros del USPSTF con una acción regulatoria concreta: HHS autoriza seis péptidos pese a objeciones de científicos de carrera de la FDA y legisladores bipartidistas piden cerrar el loophole de retatrutide knockoff. Es un cambio de postura regulatoria material para la economía de prescripción de péptidos y GLP-1 compuestos, pero acotado a esa categoría y sin reforma estructural del marco regulatorio.
- Coverage
- 1 feed · 1 independent publisher group (a single publisher group)
- Cross verticals
- Lifespan & Healthspan, Geopolitics, Investing
- Gravity vs. the previous edition
- +8 (50 → 58)
coverage, not accuracy
Lead source
STAT+: FDA adcomm members’ ties to industry under scrutiny · STAT News / Elaine ChenTimeline · Madrid time
- 18:33
- 20:00
- 16:12
- 01:23
- 22:46
- 18:47
- 14:43
- 22:36
- 10:30
- 16:07
ShareWhatsApp
Related stories
- 72GLP-1 race for obesity: Lilly against Novo Nordisk and the direct channel
- 68Cross-investment and trade restrictions in US-China biotech
- 65Federal deregulation of education in the US under Trump
- 62Oura acquires clinical care and consolidates the smart ring
- 62State Deployment of Clinical AI Without Human Oversight in the US